No Data
No Data
Unity Biotechnology Price Target Cut to $4.00/Share From $6.00 by Chardan Capital
H.C. Wainwright Maintains Unity Biotechnology(UBX.US) With Buy Rating, Cuts Target Price to $4
Mizuho Securities Maintains Unity Biotechnology(UBX.US) With Buy Rating
Positive Outlook for Unity Biotechnology Despite Initial Setback in UBX1325 Study
Sector Update: Health Care
Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint